Trilaciclib: Experimental Treatment for Triple-Negative Breast Cancer (TNBC)

Scientific rationale and therapeutic potential

Trilaciclib is a short-acting CDK4/6 inhibitor given as an intravenous infusion prior to chemotherapy. Trilaciclib is designed to:

Preclinical and clinical results (see: Publications)

Trilaciclib has potential in triple-negative breast cancer (TNBC) based on:

G1's ongoing Phase 2 trial in TNBC

                  G1T28-04 Trial  
  • first/second-line metastatic TNBC
  • multi-center, randomized, open-label
  • gemcitabine and carboplatin +/- trilaciclib
  • approximately 90 patients
  • no longer enrolling
  • identifier: NCT02978716

Click here for printable version of our trilaciclib TNBC clinical trial fact sheet